License Agreements - Additional Information (Detail) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended
	Nov. 22, 2021	Aug. 30, 2021	Dec. 31, 2021	Jan. 31, 2021	Dec. 31, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 21, 2021
Capitalized Contract Cost [Line Items]
Royalties accrued on product sales						$ 500,000	$ 200,000	$ 900,000	$ 400,000
Due to licensor (Note 8)						5,757,000		$ 5,757,000		$ 5,757,000
Right to terminate the agreement								120 days
Upfront payment				$ 14,000,000				$ 14,000,000
Total revenue					$ 14,000,000	6,202,000	3,437,000	12,069,000	5,744,000
Amount of certain development, regulatory, and sales milestones payments eligible to receive under license agreement								257,000,000
Celgene License Agreement
Capitalized Contract Cost [Line Items]
Payment of license fees		$ 5,800,000
Related party transaction, balloon payment interest rate per annum		4.00%
Celgene License Agreement | EOC Pharma (Hong Kong) Limited
Capitalized Contract Cost [Line Items]
Payment received from license agreement				$ 14,000,000.0
Celgene License Agreement
Capitalized Contract Cost [Line Items]
Payments related to milestone						$ 0	$ 0	$ 0	$ 0
License fees, percentage of previously outstanding payment obligation		50.00%
Due to licensor (Note 8)		$ 5,800,000
Celgene License Agreement | EOC Pharma (Hong Kong) Limited
Capitalized Contract Cost [Line Items]
Payments related to milestone			$ 1,000,000
Due to licensor (Note 8)											$ 200,000
Sublicense fees, percentage			20.00%	20.00%
Total revenue	$ 1,000,000